DiaCarta, a four-year-old Bay Area startup eyeing point-of-care diagnostics, said this week that it has commercially launched a line of real-time PCR test kits for somatic mutations linked to cancer.

Called QClamp, the technology uses xenonucleic acid (XNA) to "clamp," or silence, amplification of non-mutant DNA in heterogeneous samples, thus exclusively amplifying mutant DNA. The tests, currently for research use only, can be run in under two hours on existing real-time PCR platforms without a DNA extraction step, on a variety of sample types, the company claims.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.